Evidence map›Paper›PMID 9696818›Full record

ArticleJournal of virology1998

Purified, soluble recombinant mouse hepatitis virus receptor, Bgp1(b), and Bgp2 murine coronavirus receptors differ in mouse hepatitis virus binding and neutralizing activities.

B D Zelus, D R Wessner, R K Williams, M N Pensiero, F T Phibbs, M deSouza, G S Dveksler, K V Holmes

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

B D ZelusDepartment of Microbiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.
D R Wessner
R K Williams
M N Pensiero
F T Phibbs
M deSouza
G S Dveksler
K V Holmes
Uniformed Services University of the Health Sciences · USUniversity of Colorado Health · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
MOLECULAR GENETICS OF THE RECEPTOR FOR MVHR01AI025231 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLMES, KATHRYN V · 1988 to 2007
$3.5M
CORONAVIRUS-RECEPTOR INTERACTIONSR01AI026075 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLMES, KATHRYN V · 1999 to 2003
$1.3M
CORONAVIRUS/RECEPTOR INTERACTIONSU01AI026075 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLMES, KATHRYN V · 1988 to 1999
–
NCI NIH HHS P30 CA046934NCI NIH HHS P30-CA46934NIAID NIH HHS AI25231NIAID NIH HHS AI26075NIAID NIH HHS R01 AI025231NIAID NIH HHS R01 AI026075
6 · The paper itself

Abstract

Mouse hepatitis virus receptor (MHVR) is a murine biliary glycoprotein (Bgp1(a)). Purified, soluble MHVR expressed from a recombinant vaccinia virus neutralized the infectivity of the A59 strain of mouse hepatitis virus (MHV-A59) in a concentration-dependent manner. Several anchored murine Bgps in addition to MHVR can also function as MHV-A59 receptors when expressed at high levels in nonmurine cells. To investigate the interactions of these alternative MHVR glycoproteins with MHV, we expressed and purified to apparent homogeneity the extracellular domains of several murine Bgps as soluble, six-histidine-tagged glycoproteins, using a baculovirus expression system. These include MHVR isoforms containing four or two extracellular domains and the corresponding Bgp1(b) glycoproteins from MHV-resistant SJL/J mice, as well as Bgp2 and truncation mutants of MHVR and Bgp1(b) comprised of the first two immunoglobulin-like domains. The soluble four-domain MHVR glycoprotein (sMHVR[1-4]) had fourfold more MHV-A59 neutralizing activity than the corresponding soluble Bgp1(b) (sBgp1(b)) glycoprotein and at least 1,000-fold more neutralizing activity than sBgp2. Although virus binds to the N-terminal domain (domain 1), soluble truncation mutants of MHVR and Bgp1(b) containing only domains 1 and 2 bound virus poorly and had 10- and 300-fold less MHV-A59 neutralizing activity than the corresponding four-domain glycoproteins. In contrast, the soluble MHVR glycoprotein containing domains 1 and 4 (sMHVR[1,4]) had as much neutralizing activity as the four-domain glycoprotein, sMHVR[1-4]. Thus, the virus neutralizing activity of MHVR domain 1 appears to be enhanced by domain 4. The sBgp1(b)[1-4] glycoprotein had 500-fold less neutralizing activity for MHV-JHM than for MHV-A59. Thus, MHV strains with differences in S-glycoprotein sequence, tissue tropism, and virulence can differ in the ability to utilize the various murine Bgps as receptors.

Indexed as

3T3 CellsAnimalsAntigens, CDBaculoviridaeCell Adhesion MoleculesCell LineCell Line, TransformedChlorocebus aethiopsGenetic VectorsGlycoproteinsHistidineMiceMurine hepatitis virusNeutralization TestsReceptors, VirusRecombinant Fusion ProteinsAntigens, CDCD66 antigensCeacam2 protein, mouseCell Adhesion MoleculesGlycoproteinsHistidineReceptors, VirusRecombinant Fusion Proteins

Identifiers

PMID9696818
PMCPMC109946
OpenAlexW2132339087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.